BiVictriX Therapeutics PLC BiVictriX and Abzena Enter Collaboration (7391S)

TIDMBVX

RNS Number : 7391S

BiVictriX Therapeutics PLC

18 November 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

BiVictriX and Abzena Collaborate to Manufacture Antibody-Drug Conjugates

- BiVictriX has chosen Abzena for cost-effective and timely manufacturing of its antibody-drug conjugates -

Alderley Park and Cambridge, UK - 18 November 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience is pleased to announce a collaboration to manufacture BiVictriX's antibody-drug conjugates ("ADC") with Abzena Limited ("Abzena"), a partner research organisation for integrated discovery to cGMP manufacturing solutions for biologics.

The collaboration will allow BiVictriX to cost-effectively manufacture its anti-cancer ADCs for use in pre-clinical models without the need for extensive manufacturing facilities of its own. ADC production will be carried out in two cycles: the first cycle being ADC manufacturing for proof-of-concept studies; and the second cycle will cover ADC lead selection and optimisation. This collaboration has been secured just three months after BiVictriX listed on the AIM market of the London Stock Exchange, raising gross proceeds of GBP7.5 million.

Tiffany Thorn, Chief Executive of BiVictriX Therapeutics plc, commented: "Abzena is world-renowned for possessing the expertise and capabilities to develop and manufacture antibody-drug conjugates to the highest standards. Utilising Abzena's extensive knowledge in the field will be highly valuable as we look to expedite the development of our lead candidate, BVX001, and additional pipeline candidates towards achieving key pre-clinical milestones. We look forward to this initial collaboration marking the beginning of a successful and ongoing partnership with Abzena."

Campbell Bunce, Chief Scientific Officer of Abzena, said: "We're delighted to be able to support the development of BiVictriX's ADCs through our expert development, characterisation and manufacturing services. BiVictriX's "twin antigen" targeting Bi-Cygni(R) therapeutics present an innovative approach to target cancer cells and we hope to support their development as best we can."

**Ends**

 
   For more information, please contact: 
 
    BiVictriX Contacts: 
     BiVictriX Therapeutics plc 
     Tiffany Thorn, Chief Executive Officer       Email: [e-mail] 
      Iain Ross, Chairman 
     SP Angel Corporate Finance LLP (NOMAD 
      and Broker)                                  Tel: [phone] 
                                                   0470 
     David Hignell, Caroline Rowe (Corporate 
      Finance) 
      Vadim Alexandre, Rob Rees (Sales and 
      Broking) 
     Panmure Gordon (UK) Limited (Joint Broker)   Tel: [phone] 
     Rupert Dearden/Freddy Crossley/Emma Earl 
      Consilium Strategic Communications 
     Ashley Tapp, Suki Virji                      Tel: [phone] 
                                                   Email: [e-mail] 
 

Abzena Contact:

 
 Ramarketing 
 Kristy Harmer   Tel: [phone] 
                 Email: 
                  [e-mail] 
 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com

About Abzena

Abzena is a leading contract provider of integrated discovery, development and manufacturing services for biologics and bioconjugates. Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK.

Abzena investors include Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors, and Biospring Partners (https://www.biospring.com/). For more information, please see www.abzena.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBRBRTMTBBBLB

(END) Dow Jones Newswires

November 18, 2021 02:00 ET (07:00 GMT)